Reply to letter from Alvarez et al

Hum Vaccin Immunother. 2021 Mar 4;17(3):696-697. doi: 10.1080/21645515.2020.1813485. Epub 2020 Oct 29.
No abstract available

Keywords: Influenza; Quadrivalent influenza vaccine (QIV); Spain; burden of illness; cell-based vaccines; costeffectiveness; high-risk; vaccination.

Publication types

  • Letter
  • Comment

MeSH terms

  • Cost of Illness
  • Cost-Benefit Analysis
  • Humans
  • Influenza B virus / immunology
  • Influenza Vaccines*
  • Influenza, Human*
  • Spain

Substances

  • Influenza Vaccines